FORM 6-K<\/p>\n
\u00a0<\/p>\n
\nSECURITIES
\nAND EXCHANGE COMMISSION<\/p>\n
\nWashington,
\nD.C. 20549<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
\nReport
\nof Foreign Issuer<\/p>\n
\u00a0<\/p>\n
\nPursuant
\nto Rule 13a-16 or 15d-16 of<\/p>\n
\nthe
\nSecurities Exchange Act of 1934<\/p>\n
\n\u00a0<\/p>\n
\nFor the
\nmonth of July 2026\u00a0<\/p>\n
\n\u00a0<\/p>\n
\nCommission
\nFile Number: 001-11960<\/p>\n
\n\u00a0<\/p>\n
AstraZeneca PLC<\/p>\n
\n\u00a0<\/p>\n
\n1
\nFrancis Crick Avenue<\/p>\n
\nCambridge
\nBiomedical Campus<\/p>\n
\nCambridge
\nCB2 0AA<\/p>\n
\nUnited
\nKingdom<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
\nIndicate
\nby check mark whether the registrant files or will file annual
\nreports under cover of Form 20-F or Form 40-F.<\/p>\n
\u00a0<\/p>\n
\nForm
\n20-F X Form 40-F __<\/p>\n
\u00a0<\/p>\n
\nIndicate
\nby check mark if the registrant is submitting the Form 6-K in paper
\nas permitted by Regulation S-T Rule 101(b)(1):<\/p>\n
\u00a0<\/p>\n
\nIndicate
\nby check mark if the registrant is submitting the Form 6-K in paper
\nas permitted by Regulation S-T Rule 101(b)(7): ______<\/p>\n
\u00a0<\/p>\n
\nIndicate
\nby check mark whether the registrant by furnishing the information
\ncontained in this Form is also thereby furnishing the information
\nto the Commission pursuant to Rule 12g3-2(b) under the Securities
\nExchange Act of 1934.<\/p>\n
\u00a0<\/p>\n
\nYes __
\nNo X<\/p>\n
\u00a0<\/p>\n
\nIf
\n\u201cYes\u201d is marked, indicate below the file number
\nassigned to the Registrant in connection with Rule 12g3-2(b):
\n82-_____________<\/p>\n
\u00a0<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
AstraZeneca PLC<\/p>\n
\n\u00a0<\/p>\n
\nINDEX
\nTO EXHIBITS<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
1.<\/p>\n
\nAstraZeneca licenses novel EGFR inhibitor<\/p>\n
\n\u00a0<\/p>\n
\u00a014 July 2026<\/p>\n
\u00a0<\/p>\n
AstraZeneca enters exclusive global license agreement
\nfor\u00a0novel
\noral\u00a0EGFR
\ninhibitor\u00a0Zegfrovy\u00a0for lung cancer with Dizal
\nPharmaceutical<\/p>\n
\u00a0<\/p>\n
Complements AstraZeneca’s leading portfolio of medicines targeting
\nEGFR mutations<\/p>\n
\u00a0<\/p>\n
Zegfrovy is approved in the US and China to treat lung cancer
\npatients whose tumours carry exon 20 insertion
\nmutations<\/p>\n
\u00a0<\/p>\n
AstraZeneca has entered into an exclusive license agreement with
\nDizal Pharmaceutical Co., Ltd for\u00a0Zegfrovy\u00a0(sunvozertinib), a novel oral
\nirreversible\u00a0epidermal growth factor receptor
\n(EGFR)\u00a0inhibitor for patients with lung
\ncancer.\u00a0AstraZeneca will acquire worldwide rights to develop
\nand commercialise\u00a0Zegfrovy.<\/p>\n
\u00a0<\/p>\n
Zegfrovy\u00a0is approved in
\nthe US and China for the treatment of adult patients with locally
\nadvanced or metastatic non-small cell lung cancer (NSCLC)
\nwith\u00a0EGFR\u00a0exon 20 insertion mutations, whose disease
\nhas progressed on or after platinum-based
\nchemotherapy.<\/p>\n
\u00a0<\/p>\n
Approximately 80-85% of lung cancer patients globally have NSCLC.
\nAbout 10-15% of NSCLC patients in the US and Europe, and 30-40% of
\npatients in Asia, have\u00a0EGFR-mutated (EGFRm) NSCLC. Roughly one in four patients
\nwith\u00a0EGFRm NSCLC has a tumour with an\u00a0exon 20
\ninsertion mutation\u00a0or other atypical mutation for which
\ntargeted treatment options are limited.<\/p>\n
\u00a0<\/p>\n
Dave Fredrickson, Executive Vice President, Oncology Haematology
\nBusiness Unit, AstraZeneca, said: “AstraZeneca is a leader in
\ntreating\u00a0EGFR-mutated lung cancer, and we are eager to
\nadd\u00a0Zegfrovy\u00a0to our world-class portfolio of innovative
\nmedicines for patients whose tumours carry exon 20 insertion
\nmutations. With\u00a0this agreement, we will bring a
\ndifferentiated, oral targeted treatment to these patients with
\nlimited options across the globe.”<\/p>\n
\u00a0<\/p>\n
Dr.\u00a0Xiaolin Zhang, Chief Executive Officer of Dizal said: “As
\na leading global company with a strong lung cancer franchise,
\nAstraZeneca will help ensure patients around the world can benefit
\nfrom this innovation discovered by Dizal scientists in
\nChina.\u00a0Zegfrovy\u00a0is the only oral targeted therapy
\nfor\u00a0EGFR\u00a0exon 20 insertion non-small cell lung cancer
\napproved in the US and China for patients following prior systemic
\ntherapy.”<\/p>\n
\u00a0<\/p>\n
Dizal recently announced positive results from the global WU-KONG28
\nPhase III trial of\u00a0Zegfrovy\u00a0in 1st-line NSCLC with exon 20
\ninsertion\u00a0EGFR\u00a0mutations. These data were presented as a
\nLate-Breaking Abstract Oral Presentation at the 2026 American
\nSociety of Clinical Oncology Annual Meeting and simultaneously
\npublished in\u00a0The
\nNew England Journal of Medicine.<\/p>\n
\u00a0<\/p>\n
Supported by these results, a Supplemental New Drug Application for
\napproval in the 1st-line setting has been submitted to the US Food
\nand Drug Administration (FDA) and China’s Center for Drug
\nEvaluation (CDE). The US FDA and China’s CDE have also both granted
\nBreakthrough Therapy Designation to\u00a0Zegfrovy\u00a0in this setting.<\/p>\n
\u00a0<\/p>\n
Sunvozertinib (Zegfrovy)\u00a0is included in the NCCN Clinical Practice
\nGuidelines in Oncology (NCCN Guidelines\u00ae) for NSCLC as a
\nCategory 2A recommended subsequent therapy option for patients
\nwith\u00a0EGFR\u00a0exon 20 insertion mutation-positive advanced
\nor metastatic NSCLC. See NCCN Guidelines\u00ae\u00a0for detailed
\nrecommendations.1<\/p>\n
\u00a0<\/p>\n
Financial considerations<\/p>\n
\u00a0<\/p>\n
AstraZeneca will make an upfront payment to Dizal of $600m and
\nadditional payments of up to\u00a0$900m\u00a0upon achievement of specific development,
\nregulatory and sales-related milestones. Additionally, Dizal will
\nreceive tiered royalties on the global sales
\nof\u00a0Zegfrovy.<\/p>\n
\u00a0<\/p>\n
The transaction is expected to close in the second half of 2026,
\nsubject to customary closing conditions and regulatory clearances.
\nThe transaction does not impact AstraZeneca’s financial guidance
\nfor 2026.<\/p>\n
\u00a0<\/p>\n
Notes<\/p>\n
\u00a0<\/p>\n
NSCLC<\/p>\n
Lung cancer is the leading cause of cancer death among men and
\nwomen, accounting for about one-fifth of all cancer
\ndeaths.2\u00a0Lung
\ncancer is broadly split into small cell lung cancer or NSCLC, the
\nlatter accounting for 80-85% of cases.2-3\u00a0Approximately
\n75% of people are diagnosed with advanced NSCLC.4\u00a0Additionally,
\nabout 10-15% of NSCLC patients in the US and Europe, and 30-40% of
\npatients in Asia have\u00a0EGFRm NSCLC.5-7<\/p>\n
\u00a0<\/p>\n
Zegfrovy<\/p>\n
Zegfrovy\u00a0is an
\nirreversible EGFR inhibitor targeting a wide spectrum
\nof\u00a0EGFR\u00a0mutations with
\nwild-type\u00a0EGFR\u00a0selectivity.\u00a0Zegfrovy\u00a0is approved in the US and China for the
\ntreatment of adult patients with locally advanced or metastatic
\nNSCLC with\u00a0EGFR\u00a0exon 20 insertion mutations, whose disease
\nhas progressed on or after platinum-based
\nchemotherapy.<\/p>\n
\u00a0<\/p>\n
In addition,\u00a0Zegfrovy\u00a0also demonstrated encouraging anti-tumour
\nactivity in NSCLC patients with EGFR sensitizing, T790M, and
\nuncommon mutations, as well as HER2 exon 20
\ninsertions.\u00a0Zegfrovy\u00a0showed a well-tolerated and manageable
\nsafety profile in the clinic. The most common drug-related
\ntreatment-emergent adverse events were Grade 1\/2 in nature and
\nclinically manageable.<\/p>\n
\u00a0<\/p>\n
AstraZeneca in lung cancer<\/p>\n
AstraZeneca is working to bring patients with lung cancer closer to
\ncure through the detection and treatment of early-stage disease,
\nwhile also pushing the boundaries of science to improve outcomes in
\nthe resistant and advanced settings. By defining new therapeutic
\ntargets and investigating in innovative approaches, the Company
\naims to match medicines to the patients who can benefit
\nmost.<\/p>\n
\u00a0<\/p>\n
\nThe
\nCompany\u2019s comprehensive portfolio includes leading lung
\ncancer medicines and the next wave of innovations, including
\nTagrisso and Iressa (gefitinib); Imfinzi (durvalumab) and Imjudo (tremelimumab); Enhertu (trastuzumab deruxtecan) and
\nDatroway (datopotamab
\nderuxtecan) in collaboration with Daiichi Sankyo; Orpathys (savolitinib) in collaboration
\nwith HUTCHMED; as well as a pipeline of potential new medicines and
\ncombinations across diverse mechanisms of action.<\/p>\n
\u00a0<\/p>\n
AstraZeneca is a founding member of the Lung Ambition Alliance, a
\nglobal coalition working to accelerate innovation and deliver
\nmeaningful improvements for people with lung cancer, including and
\nbeyond treatment.<\/p>\n
\u00a0<\/p>\n
AstraZeneca in oncology\u00a0<\/p>\n
AstraZeneca is leading a revolution in oncology with the ambition
\nto provide cures for cancer in every form, following the science
\nto\u00a0understand\u00a0cancer and all its complexities to
\ndiscover, develop and deliver life-changing medicines to
\npatients.\u00a0<\/p>\n
\u00a0<\/p>\n
The Company’s focus is on some of the most challenging cancers. It
\nis through persistent innovation that AstraZeneca has built one of
\nthe most diverse portfolios and pipelines in the industry, with the
\npotential to catalyse changes in the practice of medicine and
\ntransform the patient experience.\u00a0<\/p>\n
\u00a0<\/p>\n
AstraZeneca has the vision to redefine cancer care and, one
\nday,\u00a0eliminate\u00a0cancer as a cause of
\ndeath.\u00a0<\/p>\n
\u00a0<\/p>\n
AstraZeneca<\/p>\n
AstraZeneca (LSE\/STO\/NYSE: AZN) is a global, science-led
\nbiopharmaceutical company that focuses on the discovery,
\ndevelopment, and commercialisation of prescription medicines in
\nOncology, Rare Disease, and BioPharmaceuticals, including
\nCardiovascular, Renal & Metabolism, and Respiratory &
\nImmunology. Based in Cambridge, UK, AstraZeneca’s innovative
\nmedicines are sold in more than 125 countries and used by millions
\nof patients worldwide. Please visit\u00a0astrazeneca.com\u00a0and
\nfollow the Company on Social Media\u00a0@AstraZeneca.<\/p>\n
\u00a0<\/p>\n
Contacts<\/p>\n
For details on how to contact the Investor Relations Team, please
\nclick\u00a0here.
\nFor Media contacts, click\u00a0here.<\/p>\n
\u00a0<\/p>\n
References<\/p>\n
\n1.\u00a0 \u00a0 \u00a0National Comprehensive
\nCancer Network. Non-Small Cell Lung Cancer. (Version
\n6.2026).\u00a0https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf.
\nAccessed July 2026. NCCN makes no warranties of any kind whatsoever
\nregarding their content, use or application and disclaims any
\nresponsibility for their application or use in any
\nway.<\/p>\n
\n2.\u00a0 \u00a0 World Health Organization.
\nInternational Agency for Research on Cancer. Lung Cancer Fact
\nSheet. Available at:\u00a0https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/15-trachea-bronchus-and-lung-fact-sheet.pdf.
\n\u00a0Accessed August 2025.<\/p>\n
\n3.\u00a0 \u00a0 American Cancer Society. What Is
\nLung Cancer?. Available at:\u00a0https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/what-is.html.
\n\u00a0Accessed August 2025.<\/p>\n
\n4.\u00a0
\n\u00a0 Chen HJ, et al. Long-term survival of advanced lung
\nadenocarcinoma by maintenance chemotherapy followed by
\nEGFR-TKI.\u00a0Medicine. 2021;100(6):e24688.<\/p>\n
\n5.\u00a0
\n\u00a0 Keedy VL, et al. American Society of Clinical Oncology
\nProvisional Clinical Opinion: Epidermal Growth Factor Receptor
\n(EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell
\nLung Cancer Considering First Line EGFR Tyrosine Kinase Inhibitor
\nTherapy.\u00a0J Clin Oncol. 2011:29;2121-27.<\/p>\n
\n6.\u00a0
\n\u00a0 Szumera-Cie\u0107kiewicz A, et al.\u00a0EGFR Mutation
\nTesting on Cytological and Histological Samples in Non-Small Cell
\nLung Cancer: a Polish, Single Institution Study and Systematic
\nReview of European Incidence.\u00a0Int J Clin Exp Pathol.
\n2013;6:2800-2812.<\/p>\n
\n7.\u00a0
\n\u00a0 Ellison G, et al. EGFR Mutation Testing in Lung Cancer: a
\nReview of Available Methods and Their Use for Analysis of Tumour
\nTissue and Cytology Samples.\u00a0J Clin Pathol.
\n2013;66:79-89.<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
Matthew Bowden<\/p>\n
Company Secretary<\/p>\n
AstraZeneca PLC<\/p>\n
\n\u00a0<\/p>\n
SIGNATURES<\/p>\n
\u00a0<\/p>\n
\nPursuant
\nto the requirements of the Securities Exchange Act of 1934, the
\nRegistrant has duly caused this report to be signed on its behalf
\nby the undersigned, thereunto duly authorized.<\/p>\n
\u00a0<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
Date: 14 July 2026<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\nBy: \/s\/
\nMatthew Bowden<\/p>\n
\u00a0<\/p>\n
\nName:
\nMatthew Bowden<\/p>\n
\u00a0<\/p>\n
\nTitle:
\nCompany Secretary<\/p>\n","protected":false},"excerpt":{"rendered":"FORM 6-K \u00a0 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 \u00a0 \u00a0 Report of Foreign Issuer \u00a0 Pursuant…\n","protected":false},"author":2,"featured_media":72847,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[11153,21721,36595,36596,28736,35519,36597,36514,36526],"class_list":["post-82757","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-astrazeneca","tag-azn","tag-egfr-exon-20","tag-license-agreement","tag-non-small-cell-lung-cancer","tag-oncology-drug","tag-royalty-deal","tag-sunvozertinib","tag-zegfrovy"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116918369895054847","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/82757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=82757"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/82757\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/72847"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=82757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=82757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=82757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}